Temocillin
ApprovedSmall molecule
Temocillin is one of 36 small molecule programs targeting Infections. It is currently in Approved.
2
Indications
8
Total Trials
1
Active Trials
35
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
163 competitors in Urinary Tract Infection
#DrugCompanyPhaseTrials
1Maxipime
PfizerPhase 3
Medrol
PfizerPhase 3
Rocephin
CConrado Roberto Hoffmann Filho
Phase 3
Decadron
AAspen Global Incorporated
Phase 3
Piperacillin/tazobactam
PfizerPhase 3
Prulifloxacin
Merck & Co.Phase 3
Amoxicillin/clavulanate Potassium
Johnson & JohnsonPhase 3
Temocillin
AAssistance Publique - Hôpitaux de Paris
Approved
Blujepa
GGlaxo Dba Glaxosmithkline
Phase 3
Imipenem+cilastatin/relebactam
Merck & Co.Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Urinary Tract Infection4 trials
Show 1 more trial
Treatment1 trial
Temocillin vs Meropenem for the Targeted Treatment of Bacteraemia Resistant to Third Gen Cephalosporins
Completed·FFundación Pública Andaluza para la gestión de la Investigación en Sevilla·Phase 3·NCT04478721·334 enrolled
PK/PD1 trial
Plasma Protein Binding and PK/PD of Total and Unbound Temocillin Non-ICU Patients
Unknown status·—·N/A·NCT03557840·60 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Temocillin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details